

Hybridoma Abs binding to HEK293-CLDN18.2




Figure 1A

Hybridoma Abs binding to HEK293-CLDN18.2




Figure 1B




Figure 1C




Figure 1D




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 3A




Figure 3B

Chimeric Abs binding to MKN45-CLDN18.2-medium




Figure 3C

Chimeric Abs ADCC effect
(Effector cell: Jurkat-NFAT-luc-FcγRIIIA-V176, Target cell: MKN45-CLDN18.2-medium)




Figure 3D




Figure 4A




Figure 4B




Figure 4C

Chimeric Abs ADCC effect
(Effector cell: Jurkat-NFAT-luc-Fc γ RIIIA-V176, Target cell: NUGC4)




Figure 4D




Figure 5




Figure 6A




Figure 6B




Figure 7A





Figure 7B

18B10 humanized Abs binding to HEK293-CLDN18.2



	18B10-HaLa	18B10-HbLa	18B10-HcLa	18B10-HaLb
EC50	1.297	1.31	1.393	1.272

18B10-HbLb	18B10-HcLb	18B10-C
1.201	1.216	1.349

Figure 8A

Humanized Abs binding to HEK293-mouse CLDN18.2




Figure 8B

Humanized Abs CDC effect on HEK293-CLDN18.2




Figure 9

18B10 humanized Abs binding to MKN45-CLDN18.2-medium




Figure 10A

ADCC reporter assay on MKN45-CLDN18.2-medium




Figure 10B




Figure 11A




Figure 11B

NUGC4 ADCC assay using PBMC (Donor ID: A18Z017017)




Figure 12




Figure 13A




Figure 13B




Figure 14A




Figure 14B

ADC cytotoxicity on MKN45-CLDN18.2-high






Figure 14C




** vs Isotype control p<0.01; ## vs IMAB362 p<0.01

Figure 15



**: vs Isotype control group $p < 0.01$; ##: vs 3mpk 18B10-HaLa group $p < 0.01$.

Figure 16



**: vs isotype control $p < 0.01$

Figure 17




Figure 18 A




Figure 18B




Figure 18 C

18B10-HaLa hIgG1 binding with hFcγRIIIA(V176)-his




Figure 18D

18B10-HaLa hIgG1 binding to Mouse FcγRI-his




Figure 18E

18B10-HaLa hIgG1 binding to Mouse Fc γ RIIB-his




Figure 18F

18B10-HaLa hIgG1 binding to Mouse Fc γ RIIIA-his




Figure 18G

18B10-HaLa hlgG1 binding to Mouse FcγRIV-his




Figure 18H

18B10-HaLa hlgG1 binding to Cyno FcγRIII-his




Figure 18I

18B10-HaLa hIgG1 binding to huFcRn-biotin




Figure 19A

18B10-HaLa hIgG1 binding to human C1q




Figure 19B

18B10-HaLa hlgG1 ADCC reporter assay on NUGC4
(E/T ratio=6:1)




Figure 20A

NUGC4 ADCC assay using PBMC (Donor ID: A18Z017017)




Figure 20B




Figure 21

NUGC4 ADCC assay using PBMC (Donor ID:A19Z028011)




Figure 22A

SNU-601 ADCC assay using PBMC (Donor ID:A19Z028011)




Figure 22B

SNU-620 ADCC assay using PBMC (Donor ID:A19Z028011)




Figure 22C

NUGC4 ADCC assay using PBMC (Donor ID:A19Z045026)





Figure 22D

ADCC reporter assay on NUGC4
(E/T ratio=6:1)



	Reference sample	18B10-HaLa low fucose	Transcient expressed 18B10-HaLa
EC50	0.02289	0.0006559	0.01421

Figure 23




Figure 24A




Figure 24B




Figure 24C




Figure 25A




Figure 25B




Figure 25C




Figure 25D




Figure 25E

PBMC (A19Z028011) mediated ADCC effect on NUGC4
10000 NUGC-4 cells, test different antibody from 40ug/ml, 5-fold 7pts, 2reps,
incubate 30min; 400000 effector cells: PBMC, incubate 5h; Kit: Promega, Cat#G1780




Figure 26A

PBMC (A19Z028011) mediated ADCC effect on SNU-601
10000 SNU-601 cells, test different antibody from 40ug/ml, 5-fold 7pts, 2reps,
incubate 30min; 400000 effector cells: PBMC, incubate 5h; Kit: Promega, Cat#G1780




Figure 26B

PBMC (A19Z028011) mediated ADCC effect on SNU-620
10000 SNU-620 cells, test different antibody from 40ug/ml, 5-fold 7pts, 2reps,
incubate 30min; 400000 effector cells: PBMC, incubate 5h; Kit: Promega, Cat#G1780




Figure 26C

PBMC (A19Z028011) mediated ADCC effect on KATOIII
10000 KATOIII cells, test different antibody from 40ug/ml, 5-fold 7pts, 2reps,
incubate 30min; 400000 effector cells: PBMC, incubate 5h; Kit: Promega, Cat#G1780




Figure 26D

Optimized PBMC-mediated ADCC assay on NUGC-4




Figure 27




Figure 28A




Figure 28B

MKN45-CLDN18.2-high tumor model




Figure 29




Figure 30A




Figure 30B




Figure 31A




Figure 31B





Figure 31C

18B10-HaLa low fucose combined with Paclitaxel on PDX xenograft model



** vs control, $p < 0.01$;
vs 18B10-HaLa low fucose, $p < 0.05$;
& vs Paclitaxel, $p < 0.05$

Figure 31D




Figure 31E




Figure 32




Figure 33A




Figure 33B

ADCC reporter assay on MIA PaCa-2-CLDN18.2




Figure 34A

ADCC reporter assay on BxPC-3-CLDN18.2





Figure 34B

MIA PaCa-2-CLDN18.2



*: 18B10-HaLa low fucose vs Isotype Control p<0.05

Figure 35

BxPC-3-CLDN18.2




Figure 36




Figure 37A




Figure 37B




Figure 38




Figure 39

NCI-H146 and PBMC co-inoculation Model




Figure 40A

Individual Tumor Volume on Day 32




Figure 40B

H460-CLDN18.2 and human PBMC co-inoculated tumor model




Figure 41




Figure 42




Figure 43